HELSINKI, Finland, July 2021. Euformatics, a bioinformatics software company providing world-leading NGS interpretation and quality control tools has found its distributor for Colombia in the shape of Quimiolab S.A.S., building a pathway for local laboratories and medical institutions to access the bioinformatic tools of the Omnomics Suite of software products.
This new agreement between the Finland-based Euformatics and the Colombian Quimiolab further cements the presence of Euformatics in Latin America, adding another country to the company’s ever-expanding list of territories in its channel partner network. Quimiolab is a distributor of instruments used for research and diagnostics with a well-established reputation amongst healthcare institutions in the country. The company is also a distributor for abm Inc. (Applied Biological Material), an Illumina certified service provider of kits and reagents used in NGS testing.
During the initial months of the COVID-19 pandemic, Quimiolab was a key player in providing instruments and equipment for detecting the SARS-CoV-2 virus in Colombia. As has been seen elsewhere, the renewed need for agile NGS testing has resulted in an increase in the overall usage of NGS equipment, in turn highlighting the need for accurate and flexible tools to be used in the tertiary stage of the NGS pipeline. Helping laboratories to fulfil these requirements is part of Euformatics’ mission to accelerate the transition to precision medicine, and this new partnership will help ensure that success in Colombia.
General Manager of Quimiolab, Liliana Ramirez, added “Both companies have been looking forward to this agreement; I believe the stage is set for the introduction of a company like Euformatics. We were impressed with the flexibility users have in designing filtering strategies for variant interpretation found in omnomicsNGS, as well as the thorough longitudinal application of quality control that is possible with omnomicsQ. We are glad to be working together with Euformatics to make sure that Colombian laboratories that want to get the most out of the NGS equipment have access to the best software tools available.”
Euformatics CEO, Tommi Kaasalainen, explained “We are confident that the expertise and human talent found Quimiolab will be the key to building the bridge between our products and Colombian diagnostic laboratories and hospitals. Colombia is one of the most promising markets for NGS technologies in Latin America and we are glad to have found a fitting partner in this territory. Through Quimiolab, we hope to contribute towards the ongoing increase in NGS implementation by means of the power offered by the Omnomics Suite.”
The recent wave of channel partner agreements has been in accordance with Euformatics’ strategy for 2021 and is an important step towards the company’s mission of accelerating the transition to precision medicine, particularly in emerging markets. Recent deals in Latin America include Brazil, Mexico, Bolivia, Paraguay and Peru.
Quimiolab is a company that has had the main purpose of becoming a strategic ally for medium and high-complexity laboratories in Colombia. A strong customer-focused approach and the constant quest for high-quality products have enabled the company to sustain leadership in its major lines of business for 25 years. Our main goal is to support diagnostic procedures with specialized tests for autoimmunity, metabolic, infectious, and genetic diseases. Currently, we have surrounded ourselves with an incredible multidisciplinary team who, from their scientific perspectives, assist the improvement of diagnostics of each laboratory.
For more information, please visit our website www.quimiolab.com
Euformatics is a Finnish software company that specialises in high standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solution is the omnomics Suite which includes omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management.
For more information, please visit our website www.euformatics.com
Christian Barreto Vargas, PhD
Alvaro Mongui Cruz, MSc/PhD